Data from the second year of the GLOBE study suggest that viral clearance within the first six months of therapy is associated with better outcomes at one and two years of treatment.
Additional results from phase III and phase IIIb studies show that CHB patients treated with telbivudine achieved greater viral clearance at 24 weeks of treatment than patients treated with either lamivudine or adefovir.
Additionally, CHB patients who switched to telbivudine achieved greater viral suppression than those who continued on lamivudine or adefovir.
The GLOBE study is a phase III clinical trial with 1,367 patients comparing telbivudine with lamivudine,
Telbivudine is called TYZEKA™ in the United States and Sebivo® in all other countries and has alerady been approved in the U.S., Switzerland, Brazil, Peru and India but still under review with the European Medicines Agency (EMEA) and the Chinese health authority.
Find more details of the clinical data from the press release.
.jpg)
Comment Preview